Blog Posts - Ombitasvir/paritaprevir/ritonavir (obv/ptv/r)



AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress™ 2015

- RUBY-I evaluates treatment-naïve, non-cirrhotic, genotype 1 chronic hepatitis C patients with severe renal impairment - In preliminary data from RUBY-I, patients receiving VIEKIRAX + EXVIERA with or without ribavirin who reached post-treatment w...
by Hepatitis C Research and News on Apr 25, 2015

U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C

- The New Drug Application (NDA) was accepted by the U.S. Food and Drug Administration (FDA) and is based on results from the PEARL-I study, which demonstrated up to 100 percent sustained virologic response rates at 12 weeks post-treatment with no di...
by Hepatitis C Research and News on Apr 24, 2015

Enanta Announces U.S. FDA Grants Priority Review for AbbVie’s Investigational, All-Oral, Interferon-Free Treatment Regimen for Genotype 4 Chronic Hepatitis C Infection

April 23, 2015 08:16 AM Eastern Daylight Time WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and...
by Hepatitis C Research and News on Apr 23, 2015


Trending Topics

Close